STOCK TITAN

Illumina to Announce Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 8, 2024

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Illumina, Inc. (ILMN) to Release Q4 and Full Year 2023 Results on February 8, 2024
Positive
  • None.
Negative
  • None.

SAN DIEGO, Jan. 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the fourth quarter and full year 2023 following the close of market on Thursday, February 8, 2024. 

On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Jacob Thaysen, Chief Executive Officer, and Joydeep Goswami, Chief Financial Officer and Chief Strategy and Corporate Development Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Conference Call Details

The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, February 8, 2024. Interested parties may access the live teleconference through the Investor Info section of Illumina's website at investor.illumina.com. Alternatively, individuals can access the call by dialing 877.400.0505 or +1.323.701.0225 outside North America, both with Conference ID 1615812. To ensure timely connection, please dial in at least ten minutes before the scheduled start of the call.

A replay of the conference call will be posted on Illumina's website after the event and will be available for at least 30 days following.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X (Twitter)FacebookLinkedInInstagramTikTok, and YouTube.

Investors:
Salli Schwartz
+1.858.291.6421
ir@illumina.com 

Media:
David McAlpine
+1.347.327.1336
pr@illumina.com 

Cision View original content:https://www.prnewswire.com/news-releases/illumina-to-announce-fourth-quarter-and-full-year-2023-financial-results-on-thursday-february-8-2024-302026672.html

SOURCE Illumina, Inc.

Illumina, Inc. (ILMN) will release its Q4 and full year 2023 results on February 8, 2024, after the close of market.

Jacob Thaysen, CEO, and Joydeep Goswami, CFO and Chief Strategy and Corporate Development Officer, will host the conference call with analysts, investors, and other interested parties.

Interested parties can access the live teleconference through the Investor Info section of Illumina's website at investor.illumina.com or by dialing 877.400.0505 or +1.323.701.0225 outside North America, both with Conference ID 1615812.

Yes, a replay of the conference call will be posted on Illumina's website after the event and will be available for at least 30 days following.
Illumina Inc

NASDAQ:ILMN

ILMN Rankings

ILMN Latest News

ILMN Stock Data

Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Analytical Laboratory Instrument Manufacturing
US
San Diego

About ILMN

at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.